PrEP Use and HIV Seroconversion Rates in Adolescent Girls and Young Women from Kenya and South Africa: the POWER Demonstration Project

Overview

Journal J Int AIDS Soc

Specialty Infectious Diseases

Date 2022 Jul 13

PMID 35822945

Authors

Connie L Celum

Elizabeth A Bukusi

Linda Gail Bekker

Sinead Delany-Moretlwe

Lara Kidoguchi

Victor Omollo

Elzette Rousseau

Danielle Travill

Jennifer F Morton

Felix Mogaka

Gabrielle OMalley

Gena Barnabee

Ariane van der Straten

Deborah Donnell

Urvi M Parikh

Lauren Kudrick

Peter L Anderson

Jessica E Haberer

Linxuan Wu

Renee Heffron

Rachel Johnson

Susan Morrison

Jared M Baeten

Affiliations

Soon will be listed here.

Abstract

Introduction: HIV incidence remains high among African adolescent girls and young women (AGYW). The primary objective of this study is to assess pre-exposure prophylaxis (PrEP) initiation, use, persistence and HIV acquisition among African AGYW offered PrEP in order to inform PrEP scale-up.

Methods: POWER was a prospective implementation science evaluation of PrEP delivery for sexually active HIV-negative AGYW ages 16-25 in family planning clinics in Kisumu, Kenya and youth and primary healthcare clinics in Cape Town and Johannesburg, South Africa. Follow-up visits occurred at month 1 and quarterly for up to 36 months. PrEP users were defined based on the month 1 refill. PrEP persistence through month 6 was assessed using Kaplan-Meier survival analysis among AGYW with a month 1 visit, defining non-persistence as an ≥15 day gap in PrEP availability for daily dosing. PrEP execution was evaluated in a subset with PrEP supply from the prior visit sufficient for daily dosing by measuring blood tenofovir diphosphate (TFV-DP) levels.

Results: From June 2017 to September 2020, 2550 AGYW were enrolled (1000 in Kisumu, 787 in Cape Town and 763 in Johannesburg). Median age was 21 years, 66% had a sexual partner of unknown HIV status, and 29% had chlamydia and 10% gonorrhoea. Overall, 2397 (94%) initiated PrEP and 749 (31%) had a refill at 1 month. Of AGYW who could reach 6 months of post-PrEP initiation follow-up, 128/646 (20%) persisted with PrEP for 6 months and an additional 92/646 (14%) had a gap and restarted PrEP. TFV-DP levels indicated that 47% (91/193) took an average of ≥4 doses/week. Sixteen HIV seroconversions were observed (incidence 2.2 per 100 person-years, 95% CI 1.2, 3.5); 13 (81%) seroconverters either did not have PrEP dispensed in the study interval prior to seroconversion or TFV-DP levels indicated <4 doses/week in the prior 6 weeks.

Conclusions: In this study of PrEP integration with primary care and reproductive health services for African AGYW, demand for PrEP was high. Although PrEP use decreased in the first months, an important fraction used PrEP through 6 months. Strategies are needed to simplify PrEP delivery, support adherence and offer long-acting PrEP options to improve persistence and HIV protection.

Citing Articles

Characterizing HIV seroconversions among a cohort of oral PrEP users in South Africa.

Martin C, Ramatsoma H, Chidumwa G, Cox L, Mullick S J Int AIDS Soc. 2025; 28(2):e26421.

PMID: 39985280 PMC: 11845853. DOI: 10.1002/jia2.26421.

Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment.

Dlamini W, Mirembe B, Krows M, Peacock S, Kotze P, Selepe P J Int AIDS Soc. 2025; 28(2):e26422.

PMID: 39956930 PMC: 11830565. DOI: 10.1002/jia2.26422.

Estimated contributions and future mitigation strategies for HIV risk around funeral practices in western Kenya: a mathematical modeling study.

Mwalili S, Gathungu D, Chemutai J, Musyoka E, Bridenbecker D, Kirkman 4th C BMC Med. 2025; 23(1):85.

PMID: 39939974 PMC: 11823116. DOI: 10.1186/s12916-025-03907-4.

Experiences with Oral Pre-Exposure Prophylaxis (PrEP) Service Delivery and Use Among Adolescent Girls and Young Women (AGYW) in Routine Primary Care Settings, South Africa.

Martin C, Muhwava L, Dada S, Scorgie F, Mullick S AIDS Behav. 2025; .

PMID: 39779628 DOI: 10.1007/s10461-024-04596-5.

High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort.

Gati Mirembe B, Donnell D, Krows M, Zwane Z, Bukusi E, Panchia R J Int AIDS Soc. 2024; 27(12):e26389.

PMID: 39653676 PMC: 11628190. DOI: 10.1002/jia2.26389.

References

Nkosi B, Seeley J, Ngwenya N, Mchunu S, Gumede D, Ferguson J . Exploring adolescents and young people's candidacy for utilising health services in a rural district, South Africa. BMC Health Serv Res. 2019; 19(1):195. PMC: 6438017. DOI: 10.1186/s12913-019-3960-1. View

Nakasone S, Chimbindi N, Mthiyane N, Nkosi B, Zuma T, Baisley K . "They have this not care - don't care attitude:" A Mixed Methods Study Evaluating Community Readiness for Oral PrEP in Adolescent Girls and Young Women in a Rural Area of South Africa. AIDS Res Ther. 2020; 17(1):55. PMC: 7487548. DOI: 10.1186/s12981-020-00310-2. View

Molina J, Charreau I, Spire B, Cotte L, Chas J, Capitant C . Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017; 4(9):e402-e410. DOI: 10.1016/S2352-3018(17)30089-9. View

Celum C, Delany-Moretlwe S, Baeten J, van der Straten A, Hosek S, Bukusi E . HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019; 22 Suppl 4:e25298. PMC: 6643076. DOI: 10.1002/jia2.25298. View

Ong J, Baggaley R, Wi T, Tucker J, Fu H, Smith M . Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; 2(12):e1917134. PMC: 6991203. DOI: 10.1001/jamanetworkopen.2019.17134. View

Hanscom B, Janes H, Guarino P, Huang Y, Brown E, Chen Y . Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. J Acquir Immune Defic Syndr. 2016; 73(5):606-608. PMC: 5175411. DOI: 10.1097/QAI.0000000000001160. View

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019; 394(10195):303-313. PMC: 6675739. DOI: 10.1016/S0140-6736(19)31288-7. View

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

10.

Reid S, Dai J, Wang J, Sichalwe B, Akpomiemie G, Cowan F . Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2009; 53(5):606-13. PMC: 2845724. DOI: 10.1097/QAI.0b013e3181bc4869. View

11.

Rousseau E, Bekker L, Julies R, Celum C, Morton J, Johnson R . A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa. BMC Health Serv Res. 2021; 21(1):888. PMC: 8403426. DOI: 10.1186/s12913-021-06920-4. View

12.

Masyuko S, Mukui I, Njathi O, Kimani M, Oluoch P, Wamicwe J . Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. Sex Health. 2018; 15(6):578-586. PMC: 7206896. DOI: 10.1071/SH18090. View

13.

. Oral abstracts of the 11th IAS Conference on HIV Science, 18-21 July 2021. J Int AIDS Soc. 2021; 24 Suppl 4:e25755. PMC: 8292786. DOI: 10.1002/jia2.25755. View

14.

Stoner M, Rucinski K, Giovenco D, Gill K, Morton J, Bekker L . Trajectories of PrEP Adherence Among Young Women Aged 16 to 25 in Cape Town, South Africa. AIDS Behav. 2021; 25(7):2046-2053. PMC: 8169554. DOI: 10.1007/s10461-020-03134-3. View

15.

Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

16.

Were D, Musau A, Mugambi M, Plotkin M, Kabue M, Manguro G . An implementation model for scaling up oral pre-exposure prophylaxis in Kenya: project. Gates Open Res. 2022; 5:113. PMC: 8669463. DOI: 10.12688/gatesopenres.13342.1. View

17.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

18.

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

19.

Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

20.

Wood K, Jewkes R . Blood blockages and scolding nurses: barriers to adolescent contraceptive use in South Africa. Reprod Health Matters. 2006; 14(27):109-18. DOI: 10.1016/S0968-8080(06)27231-8. View